Serum b Lymphocyte Activating Factor of Tumor Necrosis Super family (BAFF) and a Proliferation Inducing Ligand (April): Correlation with Activity and Chronicity Indices in Egyptian Adolescent Lupus Patients with and Without Nephritis

Title: Serum b Lymphocyte Activating Factor of Tumor Necrosis Super family (BAFF) and a Proliferation Inducing Ligand (April): Correlation with Activity and Chronicity Indices in Egyptian Adolescent Lupus Patients with and Without Nephritis

Authors: Eman Hassan Elsayed Hassan, Hanaa Mahmoud Ali Donia

DOI: http://dx.doi.org/10.18535/jmscr/v4i2.03

Abstract

References

Corresponding Author

Abstract

Dysfunction of the B lymphocyte is considered to be involved in the pathogenesis of lupus nephritis (LN) intrarenal B cells have been found in several forms of inflammatory kidney disease. B lymphocyte stimulator signaling pathway by BAFF and its homologue APRIL has an important role in the selection, maturation and survival of B cells and plays a significant role in the pathogenesis of systemic lupus erythematosus (SLE).We aim at this study to investigate the serum level of BAFF, APRIL in Egyptian adolescent lupus nephritis patients and correlate their levels with grade and chronicity indices of LN and compare their result with their counterparts of adolescent lupus patients without lupus nephritis. This study included 60 adolescent patients: Group 1: 20 adolescent SLE patients with lupus nephritis. Group 2: 20 adolescent SLE patients without lupus nephritis. Group 3: 20 age and sex matched healthy subjects served as control group. In this study, BAFF ranged from 4.26-182., 3.25-166.0 and 2.1-30.0 with the mean of 88.642.6, 69.227.6 and 12.93.25 for group I, II and III respectively, there were statistical significant differences between the three studied groups regarding BAFF, group I has statistically higher values than group II and III, also group II has statistically higher values than group III. APRIL ranged from 3.0-40.0, 2.0-42.5 and 7.0-45.0 with the mean of 7.98±8.25, 9.12±7.88 and 14.89±7.98 for group I, II and III respectively, there were statistical significant differences between the three studied groups regarding APRIL, group III has statistically higher values than group I and II, also group II has statistically higher values than group I. Regarding group I, there was positive significant correlation between ANA, activity index and chronicity index with BAFF, there was negative significant correlation between ANA, renal activity index, and chronicity index with APRIL. Regarding group II, there was positive significant correlation between ANA and Anti-DNA with BAFF, while there was negative significant correlation between ANA with APRIL.

Key Words: Adolescent SLE, lupus nephritis, BAFF, APRIL

References

1. Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005;52:2774–82.

2. Bastian HM,Roseman JM, McGwin G Jr., et al .; LUMINA Study Group. LUpus in MInority populations: NAturevs nurture. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002; 11:152–60.

3. Mok CC,Tang SS. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 2004;117:791–5.

4. Appenzeller S, Clarke AE, Panopalis P, et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol 2009;36:947–52.

5. Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:2154–60.

6. Ramanujam M, Bethunaickan R, Huang W et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010; 62:1457–68.

7. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697–710.

8. Cheema GS, Roschke V, Hilbert DM et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313–19.

9. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6–10.

10. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythem-atosus: longitudinal observations. Arthritis Rheum 2003;48:3475–86.

11. Zhao LD, Li Y, Smith MF Jr et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010;19:1534–49.

12. Vincent FB, Northcott M, Hoi A et al. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013; 22:873–84.

13. Neusser MA, Lindenmeyer MT, Edenhofer I et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 2011; 24:98–107.

14. Stein JV, Lopez-Fraga M, Elustondo FA et al. APRIL modulates B and T cell immunity. J Clin Invest 2002;109:1587–98

15. Dillon SR, Gross JA, Ansell SM et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5:235–46

16. Hegazy M, Darwish H, Darweesh H et al. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. ClinImmunol 2010;135:118–24

17. Koyama T, Tsukamoto H, Miyagi Y et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1065–7

18. Vallerskog T, Heimburger M, Gunnarsson I et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8:R167

19. Michelle Petri, Ana-Maria Orbai, Graciela S. Alarcón, Caroline Gordon, Joan T. Merrill, Paul R. Fortin, et al. Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012; 64(8): 2677–2686.

20. Maneini G, Caronora AO, Herman JF. Immunochemical quantitation of antigen by single radial immunodiffusion. Immunochemistry 1965; 2:253-7.

21. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematousus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006; 15(9): 570-6.

22. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arth Rheum 2003; 48 (4): 982-92.

23. Zapitelli M, Duffy C, Bernard C, Succimarri R, Watanabe Duffy K, Kagan R, et al. Clinicopathological study of the WHO classification in childhood lupus nephritis. PediatrNephrol. 2004; 19: 503-510.

24. SalamaA. D. and C. D. Pusey, “Drug insight: Rituximab in renal disease and transplantation,” Nature Clinical Practice Nephrology. 2006; 2: 221–230, 2006.

25. CancroM. P., D. P. D'Cruz, and M. A. Khamashta, “The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus,” Journal of Clinical Investigation.2009; 119: 1066–1073.

26. ChuV. T., P. Enghard, S. Schürer et al., “Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus,” Arthritis and Rheumatism. 2009; 60: 2083–2093.

27. Stohl W, Hilbert DM The discovery and development of belimumab: the anti-Blys-lupus connection. Nat Biotechnol. 2012;30:69–77.

28. Koyama T, Tsukamoto H, Miyani Y et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065–7.

29. Vincent FB, Northcott M, Hoi A et al. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013;22:873–84.

30. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453–2459.

31. Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y. Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices. ClinImmunol 2010; 135: 118–124.

32. Morel J, Roubille C, Planelles L, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 997–1002.

33. Stohl W, Hiepe F, Latinis KM, et al .Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328–2337.

34. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004; 50: 2048–2065.

35. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. Ann Rheum Dis 2010; 69: 1603–1611.

36. Vuyyuru R, Mohan C, Manser T, Rahman ZS The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol 2009; 183: 5716–5727.

37. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951–2962.

38. Rönnblom L. Potential role of IFNalpha in adult lupus. Arthritis Res Ther 2010; 12(Suppl 1): S3–S3.

39. Morel J, Roubille C, Planelles L, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 997–1002.

40. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328–2337.

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search